News of Note - February 24, 2023
BULL BEAR BRES|NAHAN
Friday, February 24, 2023
18:36
We’ve, just about, survived another week folks..
😊
Br. -john
*PRESS RELEASES*
SAN FP | SNY
Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. -CapIQ
PFE & BNTX
Pfizer & BioNTech
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. -CapIQ
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. -CapIQ
SAN FP | SNY
Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. -CapIQ
4568 JT & AZN LN | AZN SS | AZN
Daiichi Sankyo & AstraZeneca
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. - CapIQ
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. -CapIQ
MRK
Merck
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. -CapIQ
IIA AV & SPI AV
IMMOFINANZ & S IMMO
IMMOFINANZ: Letter of intent to sell Vienna office properties to S IMMO signed
IMMOFINANZ AG acquires, develops, owns, rents, and manages properties primarily in Austria, Germany, Poland, the Czech Republic, Hungary, Romania, Slovakia, and the Adriatic region. - CapIQ
S IMMO AG is a real estate investment company with its head office in Vienna. - CapIQ
SAABB SS
Saab
Receives Orders for Defence Equipment
The total order value is approximately SEK 8 billion with deliveries planned 2023–2026
Saab AB (publ) provides products, services, and solutions for the military defense, aerospace, and civil security markets worldwide.EKTAB SS
Elekta
Release/ Report
https://storage.mfn.se/fa1fc860-c15c-4b1c-8423-5123f4a8ddaa/elekta-q3-report-22-23.pdf
Webcast
https://elekta-qreports.creo.se/230224
Hub
https://ir.elekta.com/investors/reports-presentations/
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. -CaqIQ
AGIO
Agios
Reports Fourth Quarter and Full Year 2022 Financial Results
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. -CapIQ
NKTR
Nektar Therapeutics
FAIL
Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. -CapIQ
SOBI SS & SAN FP | SNY
Sobi & Sanofi
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. -CapIQ
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. -CapIQ
BWXT
BWX Technologies
Release
Presentation
http://s2.q4cdn.com/477932843/files/doc_financials/2022/q4/4Q22-earnings-presentation-final.pdf
Webcast
https://events.q4inc.com/attendee/587387303
BWX Technologies, Inc. manufactures and sells nuclear components in the United States, Canada, and internationally. – CapIQ
PRTA
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. - CapIQ
PEUG FP & FII FP
Peugeot Invest & LISI
To take part in the reorganisation of LISI’s ownership structure
After these transactions, Peugeot Invest may no longer own any CID shares, and it may become LISI’s second-largest shareholder with a stake of up to 16.0%.
Peugeot Invest would retain at least one seat on LISI’s Board of Directors provided that it owns more than 5% of its capital.
Peugeot Invest Société anonyme operates as an investment company. - CapIQ
Lisi S.A. provides assembly and component solutions for the aerospace, automotive, and medical industries in France and internationally. - CapIQ
MRK GY
Merck KGaA
Data from the ongoing Phase II extension showed treatment benefits of evobrutinib were maintained over four years and remained consistent with the efficacy and safety profile seen in earlier data
Evobrutinib is an investigational highly-selective, oral, CNS-penetrant BTK inhibitor with the potential to become a safe and highly efficacious treatment option for people living with RMS
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. – CapIQ
NUE
Nucor
Provides One-Year Update on New West Virginia Sheet Mill
Nucor Corporation manufactures and sells steel and steel products. - CapIQ
BPMC – ROG SW | RO SW | RHHBY
Blueprint Medicines – Roche
Should nix any thoughts of Roche taking out BPMC anytime soon..
To Regain Global Rights to GAVRETO® (pralsetinib)
Following a decision by Roche to discontinue the collaboration agreement between the companies for GAVRETO for strategic reasons
Since the initiation of the collaboration with Roche in July 2020, Blueprint Medicines has benefited from approximately $1 billion between upfront and milestone payments and from cost-sharing the commercialization and development of GAVRETO.
The company anticipates no impact to its 2023 revenue guidance, which includes $40 million to $50 million in collaboration revenues from existing collaborations, or its anticipated operating expenses in 2023.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. - CapIQ
EWTX
Edgewise Therapeutics
Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Business Highlights
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. -CapIQ
MDGL
Madrigal Pharmaceuticals
Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. - CapIQ
ALNY
Alnylam Pharmaceuticals
Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. – CapIQ
RNA
Avidity Biosciences
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. -CapIQ
ARVN
Arvinas
Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. - CapIQ
CCCC
C4 Therapeutics
Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. - CapIQ
KYMR
Kymera Therapeutics
Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. - CapIQ
ABBV
AbbVie and Capsida Biotherapeutics
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. -CapIQ
*ARTICLES, ETC.*
Evaluate
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
Nektar’s next cytokine hope follows bempe towards the bin
Conditions are ripe for reverse mergers
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
Sickle cell pipeline gets edited down
Astra buys itself a second shot at the Claudin18.2 goal
Bloomberg
Euro-Zone Core Inflation at Record Set to Embolden ECB Hawks
January underlying price gauge revised up to 5.3% from 5.2%
ECB very likely to lift deposit rate to 3% in March as planned
Stat
The FDA plans to regulate far more AI tools as devices. The industry won’t go down without a fight
Historically, the FDA’s regulation of these tools has been minimal.
The FDA’s final guidance followed two rounds of draft documents that were opened for comment, which is an unusual step for the agency.
It’s unclear when or whether FDA will target companies with products on the market that fall under the definition of devices, but never received FDA approval or clearance.
Science News
The James Webb telescope found six galaxies that may be too hefty for their age
The masses of the galaxies raise questions about how they got so big so fast
Nature
Delivering on the promise of protein degraders
Reuters
First Zantac cancer risk trial in Calif. postponed five months